

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 11/5/04Signature: *[Signature]*

(Ginny B. Jundell)

Docket No.: AREX-P01-015
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Core Patent Application of:
[Name] et al.

Application No.: 10/510361

Filed: October 5, 2004

Art Unit: N/A

For: BINDING AGENTS AND THEIR USE IN
TARGETING TUMOR CELLS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the U.S. filing date (37 CFR 1.97(b)(1)).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.




It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. AREX-P01-015.

Dated: January 5, 2005

Respectfully submitted,

By



Megan Jamroz, Ph.D.

Registration No.: 54,196

ROPES & GRAY LLP


One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/510361
				Filing Date	October 5, 2004
				First Named Inventor	Hubert Eng
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	AREX-P01-015

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number-Kind Code ⁵ (if known)			
	BA	WO	01/85204	11-15-2001	AltaRex Corp.	
	BB	EP	553244B1	08-04-1993	Medarex, Inc.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	CA	Avigan, "Dendritic cells: development, function and potential use for cancer immunotherapy," Blood Reviews 13: 51-64 (1999).		
	CB	Bjork, P., "Short Analytical Review: Development of Dendritic Cells and Their Use in Tumor Therapy", Clinical Immunology 92: 119-127 (1999).		
	CC	Coughlan et al., "Enhanced proliferation of CD4+ T cells induced by dendritic cells following antigen uptake in the presence of a specific antibody", Veterinary Immunology and Immunopathology 49: 321-330 (1996).		
	CD	Dhodapkar et al., "Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells," Journal of Clinical Investigation, 104:2, 173-180 (1999).		
	CE	Regnault et al., "Fcγ Receptor-mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I-restricted Antigen Presentation after Immune Complex Internalization," J. Exp. Med. 189:2, 371-380 (1999).		
	CF	Steinman, "The Dendritic Cell System And Its Role In Immunogenicity," Annu. Rev. Immunol. 9: 271-296 (1991).		
	CG	Timmerman et al., "Dendritic Cell Vaccines For Cancer Immunotherapy," Annu. Rev. Med. 50: 507-529 (1999).		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

9581933_1